Monoclonal antibody YS110 for refractory solid tumours.
Manjulika
M
Das
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000074322:Antineoplastic Agents, Immunological; C000621698:YS110 monoclonal antibody